Ashish Kamat, MD, MBBS, FACS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Janssen Pharmaceutical
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    ProTara
    Mitigation strategy: 
    Recusal
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Seattle Genetics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Biological Dynamics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Asieris
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Abbott Molecular
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    BMS
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    MDxHealth
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Cepheid
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023

Pages

Return to The Journal of Urology Vol. 210 (2023): November